Cargando…

Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration

PURPOSE: To detect immunoglobulins in aqueous humour of AMD patients after repeated administration of intravitreal aflibercept. PATIENTS AND METHODS: Twenty-one patients (age: 77.85 ± 9.21 years) previously treated with intravitreal aflibercept due to wet type age-related macular degeneration (AMD g...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyenes, Andrea, István, Lilla, Benyó, Fruzsina, Papp, András, Resch, Miklós, Sándor, Noémi, Józsi, Mihály, Nagy, Zoltán Z., Kovács, Illés, Kiss, Szilárd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830890/
https://www.ncbi.nlm.nih.gov/pubmed/36627583
http://dx.doi.org/10.1186/s12886-022-02761-9
_version_ 1784867759015854080
author Gyenes, Andrea
István, Lilla
Benyó, Fruzsina
Papp, András
Resch, Miklós
Sándor, Noémi
Józsi, Mihály
Nagy, Zoltán Z.
Kovács, Illés
Kiss, Szilárd
author_facet Gyenes, Andrea
István, Lilla
Benyó, Fruzsina
Papp, András
Resch, Miklós
Sándor, Noémi
Józsi, Mihály
Nagy, Zoltán Z.
Kovács, Illés
Kiss, Szilárd
author_sort Gyenes, Andrea
collection PubMed
description PURPOSE: To detect immunoglobulins in aqueous humour of AMD patients after repeated administration of intravitreal aflibercept. PATIENTS AND METHODS: Twenty-one patients (age: 77.85 ± 9.21 years) previously treated with intravitreal aflibercept due to wet type age-related macular degeneration (AMD group) and 18 age-matched control subjects (age: 69.75 ± 12.67 years) were included in this study. Patients in the AMD group received a mean of 5 intravitreal injections (min: 1 max: 17) prior to the cataract surgery. Samples of aqueous humour (50 μl) were obtained by anterior chamber paracentesis as the first step of routine cataract surgery. The IgG content of the samples was analysed by an in-house developed ELISA system. RESULTS: A significant increase in nonspecific IgG levels in the AMD group was detected compared to the control group (13.37 ± 6.65 vs. 9.44 ± 6.55 μg/ml; p = 0.03). In 11 patients, intraocular anti-aflibercept immunoglobulins could be detected (0.05 ± 0.01 μg/ml) which was significantly higher than the limit of detection for anti-aflibercept (0.04 μg/ml; p = 0.001). No correlation was found between the number of injections or the type of CNV and the aqueous level of anti-aflibercept (r = 0.02; p = 0.95). CONCLUSION: According to our results, penetration of non-specific systemic antibodies through the impaired blood-retinal barrier is higher in patients with neovascular AMD than in subjects with an intact structural barrier. Evaluation of neutralizing antibodies to anti-VEGF agents in the aqueous humour can lead us to understanding tachyphylaxis and changes in intraocular immune mechanisms due to AMD.
format Online
Article
Text
id pubmed-9830890
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98308902023-01-11 Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration Gyenes, Andrea István, Lilla Benyó, Fruzsina Papp, András Resch, Miklós Sándor, Noémi Józsi, Mihály Nagy, Zoltán Z. Kovács, Illés Kiss, Szilárd BMC Ophthalmol Research PURPOSE: To detect immunoglobulins in aqueous humour of AMD patients after repeated administration of intravitreal aflibercept. PATIENTS AND METHODS: Twenty-one patients (age: 77.85 ± 9.21 years) previously treated with intravitreal aflibercept due to wet type age-related macular degeneration (AMD group) and 18 age-matched control subjects (age: 69.75 ± 12.67 years) were included in this study. Patients in the AMD group received a mean of 5 intravitreal injections (min: 1 max: 17) prior to the cataract surgery. Samples of aqueous humour (50 μl) were obtained by anterior chamber paracentesis as the first step of routine cataract surgery. The IgG content of the samples was analysed by an in-house developed ELISA system. RESULTS: A significant increase in nonspecific IgG levels in the AMD group was detected compared to the control group (13.37 ± 6.65 vs. 9.44 ± 6.55 μg/ml; p = 0.03). In 11 patients, intraocular anti-aflibercept immunoglobulins could be detected (0.05 ± 0.01 μg/ml) which was significantly higher than the limit of detection for anti-aflibercept (0.04 μg/ml; p = 0.001). No correlation was found between the number of injections or the type of CNV and the aqueous level of anti-aflibercept (r = 0.02; p = 0.95). CONCLUSION: According to our results, penetration of non-specific systemic antibodies through the impaired blood-retinal barrier is higher in patients with neovascular AMD than in subjects with an intact structural barrier. Evaluation of neutralizing antibodies to anti-VEGF agents in the aqueous humour can lead us to understanding tachyphylaxis and changes in intraocular immune mechanisms due to AMD. BioMed Central 2023-01-10 /pmc/articles/PMC9830890/ /pubmed/36627583 http://dx.doi.org/10.1186/s12886-022-02761-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Gyenes, Andrea
István, Lilla
Benyó, Fruzsina
Papp, András
Resch, Miklós
Sándor, Noémi
Józsi, Mihály
Nagy, Zoltán Z.
Kovács, Illés
Kiss, Szilárd
Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
title Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
title_full Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
title_fullStr Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
title_full_unstemmed Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
title_short Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
title_sort intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830890/
https://www.ncbi.nlm.nih.gov/pubmed/36627583
http://dx.doi.org/10.1186/s12886-022-02761-9
work_keys_str_mv AT gyenesandrea intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration
AT istvanlilla intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration
AT benyofruzsina intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration
AT pappandras intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration
AT reschmiklos intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration
AT sandornoemi intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration
AT jozsimihaly intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration
AT nagyzoltanz intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration
AT kovacsilles intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration
AT kissszilard intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration